| Entry |
|
|---|
| Name |
Rivastigmine (JAN/USP/INN);
Exelon (TN);
Prometax (TN) |
|---|
| Product |
|
|---|
| Generic |
RIVASTIGMINE TRANSDERMAL SYSTEM (Adhexpharma), RIVASTIGMINE (Amneal Pharmaceuticals LLC), RIVASTIGMINE TRANSDERMAL SYSTEM (Breckenridge Pharmaceutical), RIVASTIGMINE TRANSDERMAL SYSTEM (Bryant Ranch Prepack), RIVASTIGMINE TRANSDERMAL SYSTEM (Bryant Ranch Prepack), RIVASTIGMINE TRANSDERMAL SYSTEM (Bryant Ranch Prepack), RIVASTIGMINE (Cadila Healthcare Limited), RIVASTIGMINE (Mylan Pharmaceuticals), RIVASTIGMINE (Northstar Rx LLC.), RIVASTIGMINE (Sandoz), RIVASTIGMINE (Zydus Pharmaceuticals (USA)), RIVASTIGMINE TRANSDERMAL SYSTEM (Alvogen) |
|---|
| Formula |
C14H22N2O2
|
|---|
| Exact mass |
250.1681
|
|---|
| Mol weight |
250.3367
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01595 Cholinesterase inhibitor
DG01593 Acetylcholinesterase inhibitor
DG01594 Butyrylcholinesterase inhibitor
DG01968 Agents for Alzheimer-type dementia
|
|---|
| Remark |
| Therapeutic category: | 1190 |
| Product (DG00984): | D03822<JP/US> D02558<US> |
|
|---|
| Efficacy |
Dementia therapeutic agent, Acetylcholinesterase inhibitor |
|---|
| Disease |
Alzheimer's disease [DS: H00056] |
|---|
| Comment |
Physostigmine derivative
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07056 | Agents for Alzheimer-type dementia |
| map07220 | Cholinergic and anticholinergic drugs |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N06 PSYCHOANALEPTICS
N06D ANTI-DEMENTIA DRUGS
N06DA Anticholinesterases
N06DA03 Rivastigmine
D03822 Rivastigmine (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antidementia Agents
Cholinesterase Inhibitors
Rivastigmine
D03822 Rivastigmine (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
119 Miscellaneous
1190 Miscellaneous
D03822 Rivastigmine (JAN/USP/INN)
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Carboxylic-ester hydrolases
ACHE
D03822 Rivastigmine (JAN/USP/INN) <JP/US>
BCHE
D03822 Rivastigmine (JAN/USP/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03822
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03822
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 18
1 C8y C 33.4600 -18.9700
2 C8x C 34.6500 -18.2700
3 C8x C 33.4600 -20.3700
4 O7a O 32.2000 -18.2700
5 C8y C 35.8400 -18.9700
6 C8x C 34.6500 -21.0700
7 C7a C 31.0100 -18.9700
8 C8x C 35.8400 -20.3700
9 N1c N 29.8200 -18.2700
10 O6a O 31.0100 -20.3700
11 C1a C 28.5600 -18.9700
12 C1c C 37.1000 -18.2700
13 N1c N 38.2900 -18.9700
14 C1a C 37.1000 -16.8700
15 C1a C 38.2900 -20.3700
16 C1a C 39.4800 -18.2700
17 C1b C 29.8200 -16.8700
18 C1a C 31.0800 -16.1700
BOND 18
1 5 8 2
2 7 9 1
3 7 10 2
4 9 11 1
5 6 8 1
6 5 12 1
7 1 2 2
8 12 13 1
9 1 3 1
10 12 14 1 #Down
11 1 4 1
12 13 15 1
13 2 5 1
14 13 16 1
15 3 6 2
16 9 17 1
17 4 7 1
18 17 18 1
|
|---|
